A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety, tolerability and antitumor activity of oral
CG-806 for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary
AML, or therapy-related AML whose disease has relapsed, is refractory or who are ineligible
for or intolerant of intensive chemotherapy or transplantation.